Antimetabolites

Comprehensive Medicinal Chemistry II

Volumn 7, Issue , 2006, Pages 55-79

  Mader, M M ^a   Henry, J R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906445172     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (141)

1. gov/dictionary (accessed Aug 2006).
2. Jemal, A.; Murray, T; Ward, E.; Samuels, A.; Tiwari, R. C.; Ghafoor, A.; Feuer, E. J.; Thun, M. J. Cancer J. Clin. 2005, 55, 10-30.
3. Ferlay, J.; Bray, F; Pisani, P.; Parkin, D. M. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Available at: http://www-depdb.iarc.fr/globocan/GLOBOframe.htm (accessed Aug 2006).
4. Ries, L. A. G.; Eisner, M. P; Kosary, C. L.; Hankey, B. F; Miller, B. A.; Clegg, L.; Mariotto, A.; Feuer, E. J.; Edwards, B. K. SEER Cancer Statistics Review, 1975-2001; National Institutes of Health. National Cancer Institute: Bethesda, MD, 2006. Available at: http://seer.cancer.gov/csr/1975-2001/ (accessed Aug 2006).
5. Foye, W O. Cancer Chemotherapeutic Agents; American Chemical Society: Washington, DC, 1995.
6. Jackman, A. L. Antifolate Drugs in Cancer Therapy; Humana Press: Totowa, NJ, 1999.
7. Santi, D. V; Danenberg, P. V. Folates in Pyrimidine Nucleotide Biosynthesis. In Folates and ; Blakely, R. L., Benkovic, S. J., Eds.; John Wiley: NewYork, 1984, pp 345-398.
8. Blakely, R. L. Dihydrofolate Reductase. In Folates and Pterins; Blakely, R. L., Benkovic, S. J., Eds.; John Wiley: NewYork, 1984, pp 191-254.
9. Schirch, V. Folates in Serine and Glycine Metabolism. In Folates and Pterins; Blakely, R. L., Benkovic, S. J., Eds.; John Wiley: New York, 1984, pp 399-432.
10. Houghton, J. A.; Harwood, F G.; Tillman, D. M. Proc. Natl. Acad. Sci. USA 1997, 94, 8144-8149.
11. Rowe, P B. Folates in the Biosynthesis and Degradation of Purines. In Folates and ; Blakely, R. L., Benkovic, S. J., Eds.; John Wiley: New York, 1984, pp 329-344.
12. Kan, J. L.; Moran, R. G. NucleicAddsRes. 1997, 25, 3118-3123.
13. Cory, J. G.; Cory, A. H.; Inhibitors of Ribonucleoside Diphosphate Reductase Activity; Pergamon: New York, 1989.
14. Holmgren, A. Annu. Rev. Biochem. 1985, 54, 237-271.
15. Cory, J. G.; Chiba, P. Pharmacol. Ther. 1985, 29, 111-127.
16. Anderson, R. D.; Kamen, B. A.; Rothberg, K. G.; Lacey, S. W Science 1992, 255, 410-411.
17. Jansen, G. Receptor-and Carrier-Mediated Transport Systems for Folates and Antifolates. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 293-321.
18. Tse, A.; Brigle, K. E.; Moran, R. G. Proc. Am. Assoc. Cancer Res. 1997, 38, 162.
19. Matherly, L. H.; Seither, R. L.; Goldman, I. D. Pharmacol. Ther. 1987, 35, 27-56.
20. McGuire, J. J. Antifolate Polyglutamation in Preclinical and Clinical Antifolate Resistance. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 339-363.
21. Montgomery, J. A. Antimetabolites. In Cancer Chemotherapeutic Agents; Foye, W O., Ed.; American Chemical Society: Washington, DC, 1995, pp 49-58.
22. Pearce, H. L. Ann. Oncol. 1995, 6, S55-S62.
23. Hirst, G. L.; Balmain, A. Eur. J. Cancer 2004, 40, 1974-1980.
24. Kamb, A. Nat. Rev. Drug Disc. 2005, 4, 161-164.
25. Kelland, L. R. Eur. J. Cancer 2004, 40, 827-836.
26. Johnson, J. I.; Decker, S.; Zaharevitz, D.; Rubinstein, L. V; Venditti, J. M.; Schepartz, S.; Kalyandrug, S.; Christian, M.; Arbuck, S.; Hollingshead, M. et al. Br. J. Cancer 2001, 84, 1424-1431.
27. Voskoglou-Nomikos, T; Pater, J. L.; Seymour, L. Clin. Cancer Res. 2003, 9, 4227-4239.
28. Booth, B.; Glassman, R.; Ma, P Nat. Rev. Drug Disc. 2003, 2, 609-610.
29. Cunningham, D.; Zalcberg, J.; Maroun, J.; James, R.; Clarke, S.; Maughan, T. S.; Vincent, M.; Schulz, J.; Gonzalez Baron, M.; Facchini, T. Eur. J. Cancer 2002, 38, 478-486.
30. Merriman, R. L.; Hertel, L. W; Schultz, R. M.; Houghton, P. J.; Houghton, J. A.; Rutherford, P. G.; Tanzer, L. P; Boder, G. B.; Grindey, G. B. Invest. New Drugs 1996, 14, 243-247.
31. Burris, H. A., III; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P. et al. J. Clin. Oncol. 1997, 15, 2403-2413.
32. Henry, J. R.; Mader, M. M. Recent Advances in Antimetabolite Cancer Chemotherapies. In Annual Reports in Medidnal Chemistry; Doherty, A. M., Ed.; Elsevier: Oxford, UK, 2004, pp 161-172.
33. Lyons, J.; Bayar, E.; Fine, G.; McCullar, M.; Rolens, R.; Rubinfield, J.; Rosenfield, C. Curr. Opin. Investig. Drugs 2003, 4, 1442-1450.
34. Moore, M. J.; Erlichman, C. Pharmacology of Anticancer Drugs. In The Basic Science of Oncology, 3rd ed.; Tannock, I. F, Hill, R. P, Eds.; McGraw-Hill: NewYork, 1998, pp 370-391.
35. Shimma, N.; Umeda, I.; Arasaki, M.; Murasaki, C.; Masubuchi, K.; Kohchi, Y; Miwa, M.; Ura, M.; Sawada, N.; Tahara, H. Bioorg. Med. Chem. 2000, 8, 1697-1706.
36. Mackean, M.; Planting, A.; Twelves, C.; Schellens, J.; Allman, D.; Osterwalder, B.; Reigner, B.; Griffin, T; Kaye, S.; Verweij, J. J. Clin. Oncol. 1998, 16, 2977-2985.
37. Ishikawa, T; Utoh, M.; Sawada, N.; Nishida, M.; Fukase, Y; Sekiguchi, F.; Ishitsuka, H. Pharmacol. 1998, 55, 1091-1097.
38. Reigner, B.; Blesch, K.; Weidekamm, E. Clin. Pharmacokin. 2001, 40, 85-104.
39. Baker, C. H.; Banzon, J.; Bollinger, J. M.; Stubbe, J.; Samano, V; Robins, M. J.; Lippert, B.; Jarvi, E.; Resvick, R. J. Med. 1991, 34, 1879-1884.
40. http://www.fda.gov/cder/foi/label/2004/020509s029lbl.pdf (accessed Aug 2006).
41. Sandler, A.; Ettinger, D. S. Oncologist 1999, 4, 241-251.
42. Storniolo, A. M.; Allerheiligen, S. R. B.; Pearce, H. L. Semin. Oncol. 1997, 24, S7-2-S7-7.
43. Chau, I. W; Cunningham, D. Clin. Lymphoma 2002, 3, 97-104.
44. Markham, M. Semin. Oncol. 2002, 29, 9-10.
45. Thigpen, T. Semin. Oncol. 2002, 29, 11-16.
46. Pfisterer, J.; Plante, M.; Vergote, I.; Du Bois, A.; Wagner, U.; Hirte, H.; Lacave, A. J.; Stahle, A.; Kimmig, R.; Eisenhauer, E. J. Clin. Oncol. 2004, 22, 5005.
47. Mutch, D. G. Gynec. Oncol. 2003, 90, S16-S20.
48. Castagneto, B.; Zai, S.; Marenco, D.; Bertetto, O.; Repetto, L.; Scaltriti, L.; Mencoboni, M.; Ferraris, V; Botta, M. Oncology 2004, 67, 27-32.
49. Tsavaris, N.; Kosmas, C.; Gouveris, P; Gennatas, K.; Polyzos, A.; Mouratidou, D.; Tsipras, H.; Margaris, H.; Papastratis, G.; Tzima, E. et al. Invest. New Drugs 2004, 22, 193-198.
50. Kaufman, D. S.; Carducci, M. A.; Kuzel, T M.; Todd, M. B.; Oh, W K.; Smith, M. R.; Ye, Z.; Nicol, S. J.; Stadler, W M. Urol.: Semin. Orig. Invest. 2004, 22, 393-397.
51. Doval, D. C.; Sekhon, J. S.; Gupta, S. K.; Fuloria, J.; Shukla, V K.; Gupta, S.; Awasthy, B. S. Br. J. Cancer 2004, 90, 1516-1520.
52. Gitlitz, B. J.; Baker, C.; Chapman, Y; Allen, H. J.; Bosserman, L. D.; Patel, R.; Sanchez, J. D.; Shapiro, R. M.; Figlin, R. A. Cancer 2003, 98, 1863-1869.
53. Montgomery, J. A.; Shortnacy-Fowler, A. T; Clayton, S. D.; Riordan, J. M.; Secrist, J. A., III. J. Med. Chem. 1992, 35, 397-401.
54. Kantaijian, H. M.; Gandhi, V; Kozuch, P; Faderl, S.; Giles, F; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F; Du, M. et al. J. Clin. Oncol. 2003, 21, 1167-1173.
55. Qian, M.; Wang, X.; Shanmuganathan, K.; Chu, C. K.; Gallo, J. M. Cancer Pharmacol. 1994, 33, 484-488.
56. Issa, J.-P.; Kantarjian, H. M.; Kirkpatrick, P. Nat. Rev. Drug Disc. 2005, 4, 275-276.
57. Paz, M. F; Fraga, M. F; Avila, S.; Guo, M.; Pollan, M.; Herman, J. G.; Esteller, M. Cancer Res. 2003, 63, 1121-1141.
58. Vidaza (Azacitidine for injectionable suspension) Prescribing Information, US Food and Drug Administration. US Government Printing Office: Washington, DC, 2004. Available at: www.fda.gov/cder/foi/label/2004/050794lbl.pdf (accessed Aug 2006).
59. Pliml, J.; Sorm, F Coll. Czech. Chem. Commun. 1964, 29, 2576-2577.
60. Saba, H.; Rosenfeld, C.; Issa, J.-P; DiPersio, J.; Raza, A.; Klimek, V; Slack, J.; de Castro, C.; Mettinger, K.; Kantarjian, H. Blood 2004, 104, Abstr. 67.
61. Cihak, A.; Vesely, J.; Hynie, S. Biochem. Pharm. 2004, 29, 2929-2932.
62. van Groeningen, C. J.; Leyva, A.; O'Brien, A. M.; Gall, H. E.; Pinedo, H. M. Cancer Res. 1986, 46, 4831-836.
63. Lambe, C. U.; Averett, D. R.; Paff, M. T; Reardon, J. E.; Wilson, J. G.; Krenitsky, T. A. Cancer Res. 1995, 55, 3352-3356.
64. Gandhi, V; Plunkett, W; Weller, S.; Du, M.; Ayres, M.; Rodriguez, C. O., Jr.; Ramakrishna, P; Rosner, G. L.; Hodge, J. P; O'Brien, S. et al. J. Clin. Oncol. 2001, 19, 2142-2152.
65. Kisor, D. F; Plunkett, W; Kurtzberg, J.; Mitchell, B.; Hodge, J. P; Ernst, T; Keating, M. J.; Gandhi, V J. Clin. Oncol. 2000, 18, 995-1003.
66. Czuczman, M. S.; Porcu, P; Johnson, J.; Niedzwiecki, D.; Canellos, G. P.; Cheson, B. D. Blood 2004, 104, Abstr. 2486.
67. Lackey, D. B.; Groziak, M. P.; Sergeeva, M.; Beryt, M.; Boyer, C.; Stroud, R. M.; Sayre, P.; Park, J. W; Johnston, P.; Slamon, D. et al. Biochem. Pharmac. 2001, 61, 179-189.
68. Sergeeva, M. V; Cathers, B. E. Biochem. Pharmacol. 2003, 65, 823-831.
69. Ecker, G. Curr. Opin. Investig. Drugs 2002, 3, 1533-1538.
70. Moore, L. E.; Boudinot, F. D.; Chu, C. K. Cancer Chemother. Pharmacol. 1997, 39, 532-536.
71. de Bono, J. S.; Stephenson, J. J.; Baker, S. D.; Hidalgo, M.; Patnaik, A.; Hammond, L. A.; Weiss, G.; Goetz, A.; Siu, L.; Simmons, C. et al. J. Clin. Oncol. 2002, 20, 96-109.
72. Jaeckle, K. A.; Phuphanich, S.; van den Bent, M. J.; Aiken, R.; Batchelor, T; Campbell, T.; Fulton, D.; Gilbert, M.; Heros, D.; O'Day, S. J. et al. Br. J. Cancer 2001, 84, 157-163.
73. Zimm, S.; Collins, J. M.; Miser, J.; Chatterji, D.; Poplack, D. G. Clin. Pharmacol. Ther. 1984, 35, 826-830.
74. Kim, S.; Chatelut, E.; Kim, J. C.; Howell, S. B.; Cates, C.; Kormanik, P A.; Chamberlain, M. C. J. Clin. Oncol. 1993, 11, 2186-2193.
75. Menei, P.; Jadaud, E.; Faisant, N.; Boisdron-Celle, M.; Michalak, S.; Fournier, D.; Delhaye, M.; Benoit, J.-P. Cancer 2004, 100, 405-10.
76. Klyosov, A. A.; Platt, D.; Zomer, E. Preclinica 2003, 1, 175-183.
77. Squeglia, A. Press Release: Pro-Pharmaceuticals reports Phase I for Davanat- http://www.pro-pharmaceuticals.com/press/pr-06-23-04.pdf (accessed Aug 2006).
78. Rosowsky, A. Development of Nonpolyglutamatable DHFR Inhibitors. In Antifolate Drugs in Cancer Therapy\ Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 59-100.
79. Gorlick, R.; Bertino, J. R. Clinical Pharmacology and Resistance to Dihydrofolate Reductase Inhibitors. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 37-57.
80. Taylor, E. C.; Kuhnt, D.; Shih, C.; Rinzel, S. M.; Grindey, G. B.; Barredo, J.; Jannatipour, M.; Moran, R. G. J. Med. Chem. 1992, 35, 4450-4454.
81. Shih, C.; Chen, V J.; Gossett, L. S.; Gates, S. B.; Mackellar, W C.; Habeck, L. L.; Shackelford, K. A.; Mendelsohn, L. G.; Soose, D. J.; Patel, V F et al. Cancer Res. 1997, 57, 1116-1123.
82. Shih, C.; Thornton, D. E. Preclinical Pharmacology Studies and the Clinical Development of a Novel Multitargeted Antifolate, MTA (LY231514). In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 183-202.
83. Worzalla, J. F; Shih, C.; Schultz, R. M. Anticancer Res. 1998, 18, 3235-4240.
84. Vogelzang, N. J.; Rusthoven, J. J.; Symanowski, J.; Denham, C.; Kaukel, E.; Ruffie, P.; Gatzemeier, U.; Boyer, M.; Emri, S.; Manegold, C. et al. J. Clin. Oncol. 2003, 21, 2636-2644.
85. Scagliotti, G. V; Shin, D.-M.; Kindler, H. L.; Vasconcelles, M. J.; Keppler, U.; Manegold, C.; Burris, H.; Gatzemeier, U.; Blatter, J.; Symanowski, J. T et al. J. Clin. Oncol. 2003, 21, 1556-1561.
86. Paz-Ares, L.; Bezares, S.; Tabernero, J. M.; Castellanos, D.; Cortes-Funes, H. Cancer 2003, 97, 2056-2063.
87. Hughes, L. R.; Stephens, T. C.; Boyle, F T; Jackman, A. L. Ralitrexed (Tomudex), a Highly Polyglutamatable Antifolate Thymidylate Synthase Inhibitor. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 147-165.
88. Elslager, E. F; Johnson, J. L.; Werbel, L. M. J. Med. Chem. 1983, 26, 1753-1760.
89. Blanke, C. D.; Kasimis, B.; Schein, P; Capizzi, R.; Kurman, M. J. Clin. Oncol. 1997, 15, 915-920.
90. Jackson, R. C.; Fry, D. W.; Bortizki, T J.; Besserer, J. A.; Leopold, W R.; Sloan, B. J.; Elslager, E. F Adv. Enzym. Reg. 1984, 22, 187-206.
91. DeGraw, J. L.; Colwell, W T; Piper, J. R.; Sirotnak, F M. J. Med. Chem. 1993, 36, 2228-2231.
92. Krug, L. M.; Azzoli, C. G.; Kris, M. G.; Miller, V A.; Khokhar, N. Z.; Tong, W; Ginsberg, M. S.; Venkatraman, E.; Tyson, L.; Pizzo, B. et al. Clin. Cancer Res. 2003, 9, 2072-2078.
93. Boritzki, T J.; Zhang, C.; Bartlett, C. A.; Jackson, R. C. AG2034, a GARFT Inhibitor with Selective Cytotoxicity to Cells that Lack a G1 Checkpoint. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 281-292.
94. Robert, F; Garrett, C.; Dinwoodie, W R.; Sullivan, D. M.; Bishop, M.; Amantea, M.; Zhang, M.; Reich, S. D. J. Clin. Oncol. 2004, 22, 3075.
95. Smith, G. K.; Bigley, J. W; Dev, I. K.; Duch, D. S.; Ferone, R.; Pendergast, W A Potent, Noncompetitive Thymidylate Synthase Inhibitor-Preclinical and Preliminary Clinical Studies. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 203-227.
96. Webber, S. E.; Bleckman, T M.; Attard, J.; Deal, J. G.; Kathardekar, V; Welsh, K. M.; Webber, S.; Janson, C. A.; Mathews, D. A.; Smith, W W et al. J. Med. Chem. 1993, 36, 733-746.
97. Hughes, A.; Calvert, A. H. Preclinical and Clinical Studies with the Novel Thymidylate Synthase Inhibitor Nolatrexed Dihydrochloride (Thymitaq™, AG337). In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 229-241.
98. Tong, Y; Banerjee, D.; Bertino, J. R. Proc. Am. Assoc. Cancer Res. 1996, 37, 384.
99. van Triest, B.; Pinedo, H. M.; Telleman, F; van der Wilt, C. L.; Jansen, G.; Peters, G. J. Biochem. Pharm. 1997, 53, 1855-1866.
100. Boyle, F T; Stephens, T C.; Averbuch, S. D.; Jackman, A. L. ZD9331-Preclinical and Clinical Studies. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 243-260.
101. Kahanic, S.; Hainsworth, J. D.; Garcia-Vargas, J. E.; Skinner, M.; Garnet, S.; Riddell, P. Proceedings of the American Society for Clinical Oncology, Orlando, FL, May 18-21, 2002; Abstr. 2682.
102. Abraham, A.; McGuire, J. J.; Galivan, J.; Nimec, Z.; Kisliuk, R. L.; Gaumont, Y; Nair, M. G. J. Med. Chem. 1991, 34, 222-227.
103. Johansen, M.; Zukowski, T; Hoff, P M.; Newman, R. A.; Ni, D.; Hutto, T.; Abbruzzeese, J.; Berghorn, E.; Hausheer, F; Madden, T Cancer Chemother. Pharmacol. 2004, 53, 370-376.
104. Cao, S.; Abraham, A.; Nair, M. G.; Pati, R.; Galivan, J. H.; Hausheer, F H.; Rustum, Y M. Clin. Cancer Res. 1996, 2, 707-712.
105. Rosowsky, A. Curr. Med. Chem. 1999, 6, 329-352.
106. Rosowsky, A.; Bader, H.; Cucchi, C. A.; Moran, R. G.; Kohler, W; Freisheim, J. H. J. Med. Chem. 1988, 31, 1332-1337.
107. Rosowsky, A.; Bader, H.; Wright, J. E.; Keyomarsi, K.; Matherly, L. H. J. Med. Chem. 1994, 37, 2167-2174.
108. Jackman, A. L.; Theti, D. S.; Gibbs, D. D. Adv. Drug. Del. Rev. 2004, 56, 1111-1125.
109. Ackland, S. P; Kimbell, R. Antifolates in Combination Therapy. In Antifolate Drugs in Cancer Therapy; Jackman, A. L., Ed.; Humana Press: Totowa, NJ, 1999, pp 365-382.
110. Bonadonna, G.; Valagussa, P; Rossi, A.; Tancini, G.; Brambilla, C.; Zambetti, M.; Veronesi, U. Breast Cancer Res. Treat. 1985, 5, 95-115.
111. Heinemann, V. Semin. Oncol. 2002, 29, 25-35.
112. Kralidis, E.; Aebi, S.; Friess, H.; Buchler, M. W; Borner, M. M. Ann. Oncol. 2003, 14, 574-579.
113. Hess, V; Salzberg, M.; Borner, M.; Morant, R.; Roth, A. D.; Ludwig, C.; Herrmann, R. J. Clin. Oncol. 2003, 21, 66-68.
114. Scheithauer, W; Schull, B.; Ulrich-Pur, H.; Schmid, K.; Raderer, M.; Haider, K.; Kwasny, W; Depisch, D.; Schneeweiss, B.; Lang, F et al. Ann. Oncol. 2003, 14, 97-104.
115. Teicher, B. A.; Chen, V; Shih, C.; Menon, K.; Forler, P. A.; Phares, V G.; Amsrud, T Clin. Cancer Res. 2000, 6, 1016-1023.
116. Giovannetti, E.; Mey, V; Danesi, R.; Mosca, I.; Del Tacca, M. Clin. Cancer Res. 2004, 10, 2936-2943.
117. Foekens, J. A.; Romain, S.; Look, M. P.; Martin, P-M.; Klijn, J. G. M. Cancer Res. 2001, 61, 1421-1425.
118. Mizutani, Y; Wada, H.; Yoshida, O.; Fukushima, M.; Nonomura, M.; Nakao, M.; Miki, T. Clin. Cancer Res. 2003, 9, 1453-1460.
119. Hosokawa, A.; Yamada, Y; Shimada, Y; Muro, K.; Hamaguchi, T; Morita, H.; Araake, M.; Orita, H.; Shirao, K. Int. J. Clin. Oncol. 2004, 9, 388-392.
120. Hu, Y C.; Komorowski, R. A.; Graewin, S.; Hostetter, G.; Kallioniemi, O.-P.; Pitt, H. A.; Ahrendt, S. A. Clin. Cancer Res. 2003, 9, 4165-4171.
121. Santini, D.; Vincenzi, B.; Perrone, G.; Rabitti, C.; Borzomati, D.; Caricato, M.; La Cesa, A.; Grilli, C.; Verzi, A.; Coppola, R. et al. Oncology 2004, 67, 135-142.
122. Devesa, S. S.; Silverman, D. T; Young, J. L., Jr.; Pollack, E. S.; Brown, C. C.; Horm, J. W; Percy, C. L.; Myers, M. H.; McKay, F W; Fraumeni, J. F, Jr. J. Nat. Cancer Inst. 1987, 79, 701-770.
123. Xeloda (Capecitabine Tablets) Prescribing Information, US Food and Drug Administration. US Government Printing Office: Washington, DC, 2000. Available at: http://www.fda/cder/foi/label/2000/20896lbl.pdf (accessed Aug 2006).
124. Alimta (Pemetrexedfor Injection) Prescribing Information. US Food and Drug Administration. US Government Printing Office: Washington, DC, 2004 Available at: http://www.fda.gov/cder/foi/label/2004/021677lbl.pdf (accessed Aug 2006).
125. Ananthan, S. Fluoropyrimidines. In Cancer Chemotherapeutic Agents; Foye, W O., Ed.; American Chemical Society: Washington, DC, 1995, pp 49-57.
126. 0-Deoxyribonucleoside Analogs. In Cancer Chemotherapeutic Agents; Foye, W O., Ed.; American Chemical Society: Washington, DC, 1995, pp 71-82.
127. Adkins, J. C.; Peters, D. H.; Markham, A. Drugs 1997, 53, 1005-1037.
128. Dearden, C. E.; Matutes, E.; Catovsky, D. Semin. Oncol. 2000, 27, 22-26.
129. Tallman, M. S.; Hakimian, D. Semin. Hematol. 1996, 33, 23-27.
130. Delfino, C.; Caccia, G.; Gonzalez, L. R.; Mickiewicz, E.; Rodger, J.; Balbiani, L.; Morales, D. F; Comba, A. Z.; Brosio, C. Oncology 2004, 66, 18-23.
131. Hoff, P M.; Ansari, R.; Batist, G.; Cox, J.; Kocha, W; Kuperminc, M.; Maroun, J.; Walde, D.; Weaver, C.; Harrison, E. et al. J. Clin. Oncol. 2001, 19, 2282-2292.
132. Twelves, C. Eur. J. Cancer 2002, 38, 15-20.
133. Sternberg, A. Curr. Opin. Investig. Drugs 2003, 4, 1479-1487.
134. Adjei, A. A. Clin. Lung Cancer 2003, 4, S64-S67.
135. Le Chevalier, T Semin. Oncol. 2003, 30, 37-44.
136. Stuart, K.; Tessitore, J.; Rudy, J.; Clendennin, N.; Johnston, A. Cancer 1999, 86, 410-14.
137. Miller, K. D.; Picus, J.; Blanke, C.; John, W; Clark, J.; Shulman, L. N.; Thornton, D.; Rowinsky, E.; Loehrer, J. S. Ann. Oncol. 2000, 11, 101-103.
138. Kindler, H. L.; Dugan, W M.; Hochster, H.; Strickland, D.; Jacobs, A.; Hayden, A. M.; Leipa, A. M.; John, W J. Am. J. Cancer 2005, 4, 185-191.
139. Schiller, J. H.; Harrington, D.; Belani, C. P; Langer, C.; Sandler, A.; Krook, J.; Zhu, J.; Johnson, D. H. N. Engl. J. Med. 2002, 346, 92-98.
140. Rusthoven, J. J.; Eisenhauer, E.; Butts, C.; Gregg, R.; Dancey, J.; Fisher, B.; Iglesias, J. J. Clin. Oncol. 1999, 17, 1194-1199.
141. Monnerat, C.; Le Chevalier, T; Kelly, K.; Obasaju, C. K.; Brahmer, J.; Novello, S.; Nakamura, T; Liepa, A. M.; Bozec, L.; Bunn, P A. et al. Clin. Cancer Res. 2004, 10, 5439-5446.